OBIO Announces 12 New OBIO CAAP® Companies for 2018

TORONTO--()--The Ontario Bioscience Innovation Organization (OBIO®) is proud to announce its 2018 Capital Access Advisory Program (CAAP®) and the 12 high-potential health science companies in this year’s cohort. Now in its sixth year, this year’s OBIO CAAP companies will work with OBIO and a vast network of expert advisors over the next year to achieve key goals and objectives which will position them for successful financing. OBIO CAAP companies are advancing and accelerating the development and commercialization of therapeutics, diagnostics, medical devices and digital health products and services to benefit Ontario and global human health.

“OBIO CAAP is a unique program for high-potential health science companies in Ontario. They receive personalized coaching, access to a global network of expert advisors, and strategic investor introductions that will ultimately drive fundraising success and lead to business and job growth,” said Gail Garland, OBIO President and CEO.

“I highly encourage any health science entrepreneur to engage with OBIO as early as possible,” said Anton Neschadim, CEO of ImmunoBiochem, a 2017 OBIO CAAP company. “During OBIO CAAP, the guidance and advice given to us was superb! The OBIO team understand and have the appropriate experience to guide life sciences companies effectively. During the OBIO CAAP year, we were provided with solid feedback on the content of our investor collaterals and strategy. There was great support and willingness to dig deep into the science, competitors, regulatory space, and truly refine our story. In summary, OBIO CAAP helped us get to a point of top investor readiness for our next round of financing."

Some of the cutting edge and high impact technologies that companies in this year’s 2018 OBIO CAAP program are developing and commercializing include: decision tools to impact treatment of cancer, mobile apps that facilitate doctor house visits, aftermarket technology that increases safety of powered wheelchairs, non-invasive digital diagnostic for skin cancer, and a transparent antibacterial adhesive film for touch screens.

Learn more about the 2018 OBIO CAAP companies, their technologies and products below:



Technology / Product


Adapsyn Bioscience

Adapsyn Bioscience has developed a bioinformatics platform that uses machine learning and microbial genomic and metabolomic data to identify novel natural products that can be developed as biomarkers or therapeutics.


Braze Mobility

Braze Mobility offers an after-market product for powered wheelchairs that increases safety by preventing collisions and offering feedback to the driver, while maximizing driver autonomy and freedom.


Bright Angel Therapeutics

Bright Angel Therapeutics is developing a novel antifungal drug platform that targets antifungal drug resistance to transform existing antifungals from ineffective to highly efficacious against all leading fungal pathogens.

Elucid Labs

Elucid is building the world’s first AI dermatology assistant (AIDA™) system as clinical decision support for early detection and non-invasive diagnosis of skin cancer and skin diseases.


HelpWear has developed HeartWatch, a clinical grade contactless ECG monitor that will contact EMS after detecting heart attacks.


LifeShield has developed a transparent antibacterial adhesive film for touch screens in hospitals and other settings which inhibits the spread of infections.


MDDT has developed TremorTek, a theranostic device to guide neurologists in treating Parkinson tremors using botulinum toxin.



MediSeen has developed a platform and app that brings back the house call allowing patients to find health care services that can be delivered at home.


Next Healthcare

Ontario based Next Healthcare Technologies has built CareCDS, a real-time information gathering platform for healthcare and pharma industry.



Polumiros has developed ReFilxTM, a polymeric filler that provides breast cancer patients a cosmetically superior and minimally-invasive solution for the restoration of tissue defects following lumpectomy.


Rna Diagnostics

Rna Diagnostics is transforming cancer treatment with their RNA Disruption Assay, a treatment response monitoring technology that allows oncologist to know early on if cancer treatment is efficacious or should be stopped.


Steadiwear has created a lightweight battery-free glove, called Steadiglove, that reduces hand tremors in Essential Tremor and Parkinson’s Disease allowing patients to do their daily activities with less frustration and more independence.


The OBIO Capital Access Advisory Program (CAAP®) is an intensive goal driven program of coaching and targeted advisor and investor introductions. The program drives fundraising success for health science companies looking to raise post-seed funding and operates downstream from existing entrepreneurship programs. It is a collaborative initiative between OBIO, industry and investors. CAAP harnesses the expertise and engagement from the Ontario health science community and investors from across Canada and the U.S. to accelerate growth of this important Ontario industry sector.

The Ontario Bioscience Innovation Organization (OBIO®) founded in 2009, is a not-for-profit, membership-based organization engaged in strategy, programming, policy development and advocacy to further the commercialization of Ontario’s human health technologies positioning Ontario as a leader in the international marketplace. OBIO advances this goal through collaborative partnerships with industry, the investment community, academia, the health system and government.

For more information, please visit and follow OBIO on Twitter @OBIOscience


Grant Burns, 416-848-6839 ext. 106
Director, Public Affairs and Communications

Release Summary

OBIO is proud to announce its 2018 Capital Access Advisory Program (CAAP®) and the 12 high-potential health science companies in this year’s cohort.



Grant Burns, 416-848-6839 ext. 106
Director, Public Affairs and Communications